Amicus Therapeutics, Inc. (OQ:FOLD)

Business Focus: Biotechnology & Medical Research

Mar 20, 2024 07:00 am ET
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report....
Mar 01, 2024 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at...
Feb 28, 2024 07:00 am ET
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2023. “In...
Feb 15, 2024 07:00 am ET
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023....
Feb 08, 2024 07:00 am ET
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
Amicus Therapeutics (Nasdaq: FOLD), today announced that WORLDSymposium™ has awarded Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) the 2024 New Treatment Award, which recognizes important achievements in advancing treatments for...
Feb 01, 2024 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in San Diego, CA. Oral Platform...
Jan 07, 2024 04:00 pm ET
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its...
Jan 03, 2024 07:00 am ET
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT. A...
Dec 05, 2023 06:00 am ET
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the...
Nov 08, 2023 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2023....
Nov 01, 2023 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. UBS Biopharma Conference in Miami, FL on Thursday, November 9, 2023, at 1:00 p.m....
Oct 27, 2023 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2023....
Oct 03, 2023 07:00 am ET
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS), being held...
Oct 02, 2023 08:20 am ET
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430...
Sep 28, 2023 10:41 am ET
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules. This two-component therapy is indicated for adults living...
Sep 01, 2023 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Monday,...
Aug 29, 2023 07:00 am ET
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held...
Aug 21, 2023 07:00 am ET
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer,...
Aug 15, 2023 07:00 am ET
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of...
Aug 08, 2023 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the second quarter ended June 30, 2023. Bradley...
Jul 31, 2023 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2023....
Jun 27, 2023 07:00 am ET
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda®...
May 10, 2023 07:00 am ET
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2023....
May 02, 2023 07:00 am ET
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care Conference in Las Vegas, NV on Thursday, May 11, 2023, at 8:40 a.m. PT. A live audio webcast of the...
May 01, 2023 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023....
Apr 26, 2023 01:00 pm ET
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme...
Mar 27, 2023 07:00 am ET
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Pombiliti™...
Mar 01, 2023 07:00 am ET
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2022. Bradley...
Feb 27, 2023 07:00 am ET
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T. A live audio webcast of the...
Feb 22, 2023 05:00 pm ET
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced positive results from the global Phase 3 open-label extension (OLE)...
Feb 14, 2023 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2022. Participants...
Feb 13, 2023 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the 19th Annual WORLDSymposium™ 2023, being held February 22-26, 2023 in Orlando, FL. Oral Platform...
Feb 08, 2023 07:00 am ET
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T. A live audio...
Jan 09, 2023 07:00 am ET
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2022 revenue, corporate updates, and...
Jan 03, 2023 07:00 am ET
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT. A...
Dec 16, 2022 08:10 am ET
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa, a...
Nov 15, 2022 07:00 am ET
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 9:45 a.m. E.T. A live audio webcast of the...
Nov 14, 2022 02:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 07, 2022 12:20 pm ET
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA. Earlier this morning, the Committee...
Nov 07, 2022 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2022. Bradley...
Oct 28, 2022 04:01 pm ET
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA. Due to restrictions on...
Oct 27, 2022 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2022....
Oct 11, 2022 07:00 am ET
Amicus Therapeutics Announces Participation at World Muscle Society 2022
Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at the 27th International Hybrid Annual Congress of the World Muscle Society, being held October...
Sep 21, 2022 07:00 am ET
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual...
Sep 08, 2022 07:00 am ET
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on Wednesday, September 14, 2022 at 12:20 p.m. E.T. A live audio...
Aug 04, 2022 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2022. Bradley...
Jul 26, 2022 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022. Interested...
Jun 08, 2022 07:00 am ET
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15, 2022 at 11:20 a.m. P.T. A live...
May 10, 2022 04:01 pm ET
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA)...
May 09, 2022 09:15 am ET
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
In a release issued under the same headline earlier today by Amicus Therapeutics, Inc., (Nasdaq: FOLD) please note that in the third bullet under the First Quarter 2022 Financial Results section, the Total GAAP operating expenses should be $146.5...
May 09, 2022 07:00 am ET
Amicus Therapeutics Announces First Quarter 2022 Financial Results
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended March 31, 2022....
May 04, 2022 07:00 am ET
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, 2022 at 12:00 p.m. P.T. A live audio webcast of the...
Apr 26, 2022 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022. Interested...
Apr 19, 2022 07:00 am ET
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued...
Mar 16, 2022 07:00 am ET
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
Amicus Therapeutics (Nasdaq: FOLD), today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an...
Mar 10, 2022 07:00 am ET
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in...
Mar 01, 2022 07:00 am ET
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T. A live audio...
Feb 24, 2022 07:00 am ET
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Marke
ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus...
Feb 24, 2022 07:00 am ET
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full year ended December 31, 2021. John F....
Feb 10, 2022 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2021....
Feb 07, 2022 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that two oral presentations and 11 posters across its development...
Jan 10, 2022 07:00 am ET
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2021 revenue, corporate updates, and...
Jan 05, 2022 07:00 am ET
Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T. A live audio webcast of the presentation...
Dec 03, 2021 07:00 am ET
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease....
Nov 24, 2021 07:00 am ET
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T....
Nov 22, 2021 07:00 am ET
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021. Digital Poster...
Nov 18, 2021 07:00 am ET
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the data from the Phase 3 PROPEL pivotal trial, assessing the...
Nov 11, 2021 07:00 am ET
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T. A live audio...
Nov 09, 2021 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2021....
Nov 03, 2021 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021....
Oct 19, 2021 02:00 pm ET
MERGER ALERT – DUNE, and FOLD: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Sep 29, 2021 08:30 am ET
Thinking about buying stock in Applied UV, Fortress Biotech, Geovax Labs, Amicus Therapeutics, or Lucid Group?
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, FBIO, GOVX, FOLD, and LCID.
Sep 29, 2021 06:30 am ET
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) today announced its intent to launch a next-generation genetic medicine company, Caritas Therapeutics, Inc., (“Caritas”) through a definitive business combination agreement pursuant to which the...
Sep 29, 2021 06:30 am ET
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for...
Sep 20, 2021 07:00 am ET
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, September...
Sep 03, 2021 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Morgan Stanley 19th Annual Global...
Aug 05, 2021 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2021. John...
Aug 04, 2021 07:00 am ET
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T. A live audio webcast...
Aug 02, 2021 07:00 am ET
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold® (migalastat)...
Jul 27, 2021 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021....
Jun 14, 2021 07:00 am ET
Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience...
Jun 08, 2021 07:00 am ET
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the UK’s Medicines and Healthcare Products Regulatory...
May 28, 2021 07:00 am ET
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually on Wednesday, June 9, 2021...
May 21, 2021 07:00 am ET
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May 21-22 and 28-29,...
May 10, 2021 07:00 am ET
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the quarter ended March 31, 2021. John...
May 07, 2021 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: Bank of America 2021 Health Care Conference on...
May 06, 2021 07:00 am ET
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company’s corporate strategy and business and corporate development...
May 05, 2021 07:00 am ET
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy 24th Annual Meeting being held virtually, May 11-14, 2021. Accepted abstracts will highlight...
May 03, 2021 07:00 am ET
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
Amicus Therapeutics (NASDAQ:FOLD) today announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for AT-GAA (cipaglucosidase alfa co-administered with...
Apr 28, 2021 07:00 am ET
Amicus Therapeutics Recognized as a Great Place to Work® in Europe
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to...
Apr 26, 2021 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2021. Interested...
Mar 15, 2021 07:00 am ET
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference
Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held March 15-18, 2021....
Mar 01, 2021 07:00 am ET
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full year ended December 31, 2020....
Feb 18, 2021 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences: SVB Leerink 10th Annual Global Healthcare Conference...
Feb 17, 2021 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 1, 2021 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2020. Interested...
Feb 11, 2021 04:01 pm ET
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPE
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the topline results of its Phase 3 PROPEL Pivotal Trial for...
Feb 08, 2021 02:30 pm ET
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced positive initial results from its first in-human study of its CLN3 Batten disease gene therapy program, AT-GTX-502. The results are featured in a virtual poster presentation at the 17th Annual...
Feb 08, 2021 02:30 pm ET
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Fabry disease in mice. The results are featured in a virtual poster presentation at the 17th...
Jan 21, 2021 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its...
Jan 11, 2021 07:00 am ET
Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today provided preliminary, unaudited Galafold revenue for the full-year 2020...
Jan 05, 2021 07:00 am ET
Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually on Tuesday, January 12, 2021 at 8:20 a.m. ET. A...
Dec 07, 2020 07:00 am ET
Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been nationally recognized as a Great Place to...
Dec 02, 2020 07:00 am ET
Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors
Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in...
Dec 01, 2020 07:00 am ET
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the initiation of the rolling Biologics License Application...
Nov 23, 2020 07:00 am ET
Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15...
Nov 05, 2020 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the third quarter ended September 30,...
Nov 02, 2020 07:00 am ET
Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET. A live audio...
Oct 22, 2020 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2020....
Oct 12, 2020 07:00 am ET
Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program, AT-GTX-501. The results are featured in a virtual poster presentation at the Joint 16th International Child...
Sep 24, 2020 07:00 am ET
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has granted Priority...
Sep 03, 2020 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Citi’s 15th Annual BioPharma Virtual...
Aug 10, 2020 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the second quarter ended June 30, 2020....
Aug 04, 2020 07:00 am ET
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T. A live audio...
Jul 28, 2020 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020. The call...
Jul 17, 2020 07:32 am ET
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has executed a definitive agreement for a $400...
Jun 04, 2020 07:00 am ET
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held virtually on Wednesday,...
May 08, 2020 07:00 am ET
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020 Annual Meeting of Stockholders will now be held...
May 07, 2020 07:00 am ET
Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2020....
May 06, 2020 07:00 am ET
UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of several abstracts for presentation at the...
May 05, 2020 07:00 am ET
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of several abstracts for presentation at the...
Apr 24, 2020 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2020. The call will...
Mar 23, 2020 07:00 am ET
Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company has proactively taken numerous measures in...
Mar 05, 2020 07:00 am ET
Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
Amicus Therapeutics (Nasdaq: FOLD) today announced the official opening of the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia to advance its industry leading portfolio of rare disease gene therapy...
Mar 02, 2020 07:00 am ET
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019....
Feb 26, 2020 07:00 am ET
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live...
Feb 19, 2020 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019. The call will...
Feb 07, 2020 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020
Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its...
Jan 13, 2020 07:00 am ET
Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today provided its full-year 2020 strategic outlook and financial guidance....
Jan 09, 2020 07:00 am ET
Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global, patient dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced preliminary 2019 revenue and Galafold (migalastat)...
Jan 07, 2020 07:00 am ET
Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced clinical, regulatory and manufacturing advancements...
Nov 11, 2019 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2019. The...
Oct 30, 2019 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019. The...
Oct 24, 2019 07:00 am ET
Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. The results are...
Oct 10, 2019 07:30 am ET
Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
Amicus Therapeutics (Nasdaq: FOLD) today announced preliminary unaudited revenue for the third quarter of 2019 in advance of its Analyst Day, to be held today, October 10, 2019, in New York City at 8:30 a.m. Today’s Analyst Day will highlight the...
Oct 02, 2019 07:00 am ET
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an...
Oct 01, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences: An oral presentation highlighting Phase 1/2 results, including cohort 4, for...
Sep 04, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell, President and Chief Operating Officer, and Jeff Castelli, Chief Portfolio Officer and Head of Gene...
Aug 08, 2019 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2019. The...
Aug 02, 2019 07:00 am ET
Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Agency of Medicines, Food and Medical Devices (ANMAT) in Argentina has granted approval for the first-in-class, oral small molecule pharmacological chaperone Galafold® (migalastat), as a...
Aug 01, 2019 06:00 am ET
Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. AWRI is conducting the...
Jul 29, 2019 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2019. The call...
Jul 02, 2019 07:30 am ET
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity for multiple active preclinical lysosomal...
Jul 01, 2019 07:00 am ET
Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific1. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with late-stage clinical and...
Jun 13, 2019 07:30 am ET
Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Senior Leadership Team. Jill Weimer, PhD, a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has...
Jun 04, 2019 04:01 pm ET
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of its common stock, including 2,441,860 shares of common stock sold pursuant to...
Jun 03, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming Scientific Conference: Michael C. Diem, MD, Senior Vice President of Business and Corporate...
May 30, 2019 09:00 pm ET
Amicus Therapeutics Prices Underwritten Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before...
May 29, 2019 04:14 pm ET
Amicus Therapeutics Announces Public Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers...
May 29, 2019 06:30 am ET
Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
Amicus Therapeutics (Nasdaq: FOLD) and the Perelman School of Medicine at the University of Pennsylvania (Penn) today announced a major expansion to their collaboration with rights to pursue collaborative research and development of novel gene...
May 13, 2019 05:00 pm ET
Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations.  He has...
May 10, 2019 07:00 am ET
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14,...
May 08, 2019 07:00 am ET
Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the first quarter ended March 31, 2019. The...
Apr 30, 2019 06:00 am ET
Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in mice. These data will be highlighted in a poster (Poster 82, Abstract 518)...
Apr 25, 2019 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2019. The call will...
Apr 15, 2019 12:00 pm ET
Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene & Cell...
Mar 29, 2019 07:10 am ET
Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Com
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Below, Inc. (NASDAQ:FIVE), INVESCO MORTGAGE CAPITAL INC (NYSE:IVR),...
Mar 20, 2019 07:00 am ET
Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase...
Feb 28, 2019 07:00 am ET
Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the full year ended December 31, 2018. The...
Feb 26, 2019 07:00 am ET
Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
Amicus Therapeutics (Nasdaq: FOLD) today announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to world-class science that makes a meaningful...
Feb 25, 2019 04:00 am ET
U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted to Amicus a Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal...
Feb 13, 2019 07:30 am ET
New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Clovis Oncology, Inc....
Feb 12, 2019 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2018. The call...
Feb 05, 2019 04:01 pm ET
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme...
Jan 18, 2019 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its...
Jan 10, 2019 07:30 am ET
Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX), Amicus Therapeutics, Inc. (NASDAQ:FOLD),...
Jan 07, 2019 07:00 am ET
Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today provided unaudited preliminary Galafold revenue for the full-year 2018 and...
Jan 03, 2019 04:01 pm ET
Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8,...
Jan 03, 2019 07:00 am ET
Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the initiation of a Phase 1/2 clinical study to evaluate the safety...
Dec 20, 2018 07:00 am ET
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the dosing of the first patient in a global phase 3 clinical study...
Dec 19, 2018 04:01 pm ET
Amicus Therapeutics Announces Executive Team Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Daphne Quimi will be promoted to Chief Financial Officer,...
Dec 11, 2018 04:01 pm ET
Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® (Migalastat)
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Galafold® (migalastat) was awarded the 2018 UK Prix Galien Medal...
Dec 04, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xencor, Inc. (NASDAQ:XNCR), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC),...
Nov 12, 2018 07:00 am ET
Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on Wednesday, November...
Nov 05, 2018 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2018. The...
Oct 29, 2018 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018. The...
Oct 25, 2018 09:25 am ET
Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences — Renewed Outlook, Key Driv
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PennyMac Mortgage Investment Trust (NYSE:PMT), Amicus Therapeutics,...
Oct 11, 2018 07:00 am ET
Amicus Therapeutics to Host Analyst Day 2018 Today in New York City
Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases will host its Analyst Day today, October 11, 2018, in New York City from 8:30...
Oct 08, 2018 07:00 am ET
Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
Amicus Therapeutics (Nasdaq: FOLD) today announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to pursue research and development of novel gene therapies for Pompe...
Oct 05, 2018 07:00 am ET
Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme...
Oct 02, 2018 07:00 am ET
Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society, to be held...
Sep 26, 2018 07:00 am ET
Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease Oncology in New York, NY on...
Sep 25, 2018 07:55 am ET
Report: Exploring Fundamental Drivers Behind Ocean Power Technologies, Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, Fanhua, and Parsley Energy — New Horizons, Emerging Trends, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ocean Power Technologies, Inc. (NASDAQ:OPTT), Amicus Therapeutics, Inc....
Sep 20, 2018 06:00 am ET
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
Amicus Therapeutics (Nasdaq: FOLD) today announced the signing of a definitive agreement in which Amicus Therapeutics will receive worldwide development and commercial rights for ten gene therapy programs developed at The Center for Gene Therapy at...
Sep 11, 2018 07:00 am ET
Amicus Therapeutics Announces Board Appointments
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the appointment of Lynn D. Bleil to its Board of Directors, effective...
Sep 10, 2018 07:00 am ET
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program AT-GAA...
Aug 31, 2018 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September. Bradley Campbell, President and Chief Operating Officer, and Chip Baird, Chief Financial Officer, will present a corporate overview...
Aug 10, 2018 04:05 pm ET
FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Galafold™ (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with...
Aug 07, 2018 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2018. The...
Jul 31, 2018 07:40 am ET
Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Interpace Diagnostics Group, Inc....
Jul 31, 2018 07:30 am ET
Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2018. The call...
Jul 30, 2018 08:00 am ET
Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of General Dynamics Corporation (NYSE:GD), General Motors Company (NYSE:GM),...
Jun 26, 2018 04:05 pm ET
Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for...
Jun 08, 2018 07:00 am ET
Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of  the Company’s President and Chief...
Jun 01, 2018 07:00 am ET
Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference in...
May 30, 2018 12:00 am ET
Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan
Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry...
May 09, 2018 07:30 am ET
Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15,...
May 08, 2018 07:00 am ET
Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the first quarter ended March 31, 2018. The...
Apr 26, 2018 07:30 am ET
Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended...
Apr 17, 2018 07:30 am ET
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to...
Apr 16, 2018 07:55 am ET
Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco — Future Expectations, Projections Moving into 2018
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Rite Aid...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.